Ignite Creation Date:
2024-05-06 @ 6:29 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05686759
Status:
RECRUITING
Last Update Posted:
2023-02-14
First Post:
2022-12-02
Brief Title:
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of IV-Hepabig Inj
Sponsor:
GC Biopharma Corp
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of IV-Hepabig Inj in Post-liver Transplant Patients
Status:
RECRUITING
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of IV-Hepabig inj in post-liver transplant patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None